role of menopause are still open to discussion (Barrett-Connor The relationship between menopause and non-fatal acute and Bush, 1991; La Vecchia, 1992) . myocardial infarction (AMI) was considered by analysing A protective role of female sex hormones on CHD is data from a case-control study conducted in Italy between supported by the observation that hormonal changes related to 1983 and 1992. Cases were 429 women, below age 75 years, menopause unfavourably alter the profile of some cardiowith a first episode of non-fatal AMI, admitted to 30 vascular risk factors (La Vecchia, 1992; Gensini et al., 1998 ; coronary care units; controls were 863 women admitted to Greendale et al., 1999) . These include increased concentrations the same network of hospitals for acute diseases other than of cholesterol, triglycerides, low-density lipoproteins, and cardiovascular, neoplastic, or hormone-related. Postapolipoprotein-B, reduced levels of high-density lipoproteins menopausal women were not at higher risk of AMI than and higher blood pressure (Davis et al., 1994; Schaefer et al. , pre/perimenopausal women, after adjustment for age and 1994; Dallongeville et al., 1995) .
Oestrogens have been other selected covariates [multivariate odds ratio (OR)
reported to promote vasodilatation through several biological 0.99]. With reference to age at menopause, compared mechanisms, and to inhibit the development and progression with women reporting menopause when <45 years, the of atherosclerosis (Mendelsohn and Karas, 1999) . Moreover, multivariate OR were 1.54 for those aged 45-49 at menomenopausal hormone replacement therapy (HRT) has been pause, 1.36 for those aged 50-52 years, and 0.97 for those associated with a reduction in CHD incidence and mortality aged ≥53, in the absence of any trend in risk. No meaningful in women with no previous cardiovascular events in several relationship emerged with time since menopause (OR 0.85 observational studies (Stampfer et al., 1991;  The Writing for <10 years since menopause). The results were similar Group for the PEPI Trial, 1995; Grodstein et al., 1996 ; Barrettin women aged <60 and ≥60 years at AMI. Although the Connor, 1998) . Conversely, intervention trials on women with present study does not support a substantial relationship previous CHD or at high risk of CHD show no appreciable between menopause and non-fatal AMI, the overall reduction of risk (Hemminki and McPherson, 1997 ; Hulley epidemiological evidence is compatible with a moderate Petitti, 1998) . association.
Introduction
Materials and methods The hypothesis that menopause and consequent biological The present study is based on the data of a case-control study on modifications are related to the risk of coronary heart disease AMI, conducted in Italy between 1983 and 1992, whose general (CHD) originally derived from the observation that incidence design has already been described (La Vecchia et al., 1987a,b, and mortality rates for cardiovascular disease (CVD) in women 1989). Originally, the study focused on oral contraceptives and other are substantially lower than in men before menopause, but hormonal factors, and hence had an upper age limit of 54 years. This tend to rise and approach those of men at older ages (Heller limit Controls were 863 women, aged 17-79 (median age 52 years), admitted to the same network of hospitals for acute diseases other a Estimates from multiple logistic regression equations including terms for age, study, education, smoking habits, body mass index, diabetes, than cardiovascular, neoplastic, digestive, and hormone-related condihypertension, hyperlipideamia and hormone replacement therapy.
tions, or diseases associated with long-term changes in the diet. Of b Reference category. these, 25.3% were admitted for traumatic conditions, 36.4% had nonc The sum does not add up to the total because of some missing values. traumatic orthopaedic disorders (mostly low-back pain and disc disorders); 15.5% had acute surgical conditions; and 22.8% had other illnesses such as acute infections, skin, eye, ear, nose, and throat, or index, and use of HRT. Educational level was similar in AMI dental disorders. Cases and controls were not singly matched by age, cases and controls. Cases were more frequently overweight but the frequency distribution by quinquennia of age was comparable.
(47.7% versus 41.1% of controls had a BMI ജ25), and reported Less than 5% of cases and controls approached for interview refused.
HRT use (mostly short-term) more often than controls. These those aged ജ53, in the absence of any trend in risk (P for trend 0.997). The OR for one year of increment in age at Data analysis menopause was 1.01 (95% CI 0.98-1.04). No relationship Odds ratios (OR) of AMI according to menopausal status and age at between age at menopause and risk of AMI emerged when menopause, and the corresponding 95% confidence intervals (CI), women aged Ͻ60 and ജ60 years at interview were analysed were derived using unconditional multiple logistic regression, fitted separately. With reference to time since menopause, compared by the method of maximum likelihood (Breslow and Day, 1980) . All to pre/perimenopausal women the OR was 0.85 for those the regression equations included terms for study, age (quinquennia reporting menopause Ͻ10 years earlier, and 0.52 for those plus a continuous term, to obtain a more detailed allowance), whose menopause dated back ജ20 years. education, smoking, body mass index (BMI), history of diabetes, hypertension and hyperlipidaemia, and use of HRT.
Discussion

Results
This is a hospital-based case-control study with all the inherent strengths and limitations. However, cases were women with Table I gives the distribution of 429 non-fatal AMI cases and 863 control women according to age, education, body mass AMI diagnosed according to strictly defined criteria (WHO, (non-fatal) postmenopause 1 (reference) hypertension, cholesterol, diabetes, body mass preϩperimenopause 0.5 (0.2-0.9) index, family history, physical activity, alcohol, menopause at age ജ50 1 (reference) coffee and HRT. years menopause at age Ͻ45 years natural 2.1 (1.3-3.2) surgical 1.7 (1.0-2.7)
AMI ϭ acute myocardial infarction; CHD ϭ coronary heart disease; HRT ϭ hormone replacement therapy; IHD ϭ ischaemic heart disease; OC ϭ oral contraceptives; OR ϭ odds ratio; RR ϭ relative risk; CI ϭ confidence interval.
1971), and any bias in the selection of controls should be limited either at young (35-40 years) or old age (56-60 years), the association being apparently stronger in non-HRT users. because we specifically excluded any hospital admission for Two case-control studies investigated the relationship diseases potentially related to recognized cardiovascular risk between menopause and AMI risk. An OR of 0.6 (95% CI factors. As for other potential sources of bias, participation 0.4-1.0) was found in postmenopausal women compared with was almost complete, cases and controls were drawn from the premenopausal ones (Rosenberg et al., 1983) , and an OR of same catchment areas, the interviews were conducted for cases 0.5 (95% CI 0.2-0.9) was found in pre-and perimenopausal and controls during the hospital stay, and the questionnaire women compared to postmenopausal ones (Palmer et al., was tested for reproducibility (D'Avanzo et al., 1997) . Informa-1992) , with higher risks in women with menopause at age tion on status and age at menopause has been shown to be Ͻ45 years than in women with menopause at age ജ50 years. reliable and valid (Bean et al., 1979; Rosenberg et al., 1979) , Thus, there is some suggestion that postmenopausal women and separate information was collected on type of menopause may have a higher risk of CHD, although there is substantial to distinguish women with simple hysterectomy from those heterogeneity in the results across various studies. This is not with bilateral oophorectomy (Pike et al., 1998) . Thus, the easily explained by the different types of study (cohort or results are not likely to be influenced by selection or information case-control), the inclusion of fatal or non-fatal diseases, the bias. Allowance for major identified potential confounding inclusion of HRT users, the cut-off points selected for age factors, including education, smoking, body mass index, at menopause and other identified factors. Some of these selected diseases and use of HRT did not materially modify discrepancies may be the result of difficulties in the collection the risk estimates, and very detailed allowance was made for and analysis of epidemiological data on menopause. Besides age (quinquennia plus a continuous term) to avoid potential uncertainties in the definition of the perimenopausal period, underadjustment (Pike, 1987) .
age at menopause is difficult to establish in women after The overall epidemiological evidence on the relationship hysterectomy and in those using HRT. Moreover, like any between menopause and CHD is still controversial. Most other time-related factor, it is important to make an extremely information derives from seven cohort and two case-control detailed age-adjustment for an unbiased quantification of risk studies, and is summarized in Table III . As for the cohort (Pike, 1987) . studies, the 20-year follow-up of the Framingham Study Some hormonal changes at menopause might influence the showed a twofold increase in relative risk (RR) in post-versus risk of CVD. HRT may be protective for atherosclerosis and premenopausal women (Kannel et al., 1976) ; in the 24-year other cardiovascular risk factors (Writing Group for the PEPI follow-up of this cohort, based on 43 cases of fatal and nontrial, 1995; McCrohon et al., 1996) , but may also be thrombofatal AMI, the AMI incidence rate was 1.4 in premenopausal genic, as suggested by the short-term excess risk after starting and 3.9 in postmenopausal women (Gordon et al., 1978) . In a HRT use in the Heart and Estrogen/Progestin Replacement cohort of Swedish women (Lapidus et al., 1985) , based on 25
Study (Daly et al., 1996; Jick et al., 1996 ; Perez Gutthann cases of AMI, the RR were 2.0 (95% CI 0.2-19.1) for women et al., 1997). Other potential effects include modifications of aged ഛ40 years at menopause, 2.2 (95% CI 0.7-7.4) and 1.4 plasma lipid profile (Hulley et al., 1998) , fibrinolysis (Petitti, (95% CI 0.5-3.8) for women aged ഛ45 and ഛ50 years, 1998) and blood pressure (Hazzard, 1989) ; however, the compared to premenopausal women. In the follow-up at 6 potential role of such modifications on the risk of CVD is still years of the American Nurses' Health cohort study (Colditz undefined. et al., 1987) , compared to premenopausal women, those with
In conclusion, this study does not support a substantial natural menopause had an RR of 1.1 and those with surgical relationship between age at menopause and non-fatal AMI; menopause had an RR of 1.7 when HRT had never been used, the overall epidemiological evidence is compatible with a and respectively RR of 0.8 and 0.7 when only HRT users were moderate association between menopausal age and risk of included. In a study from Tromsø in Norway (Jacobsen et al., CHD, also supported by the benefit reported for use of HRT 1997), including 2767 cases of CHD, the RR was 0.84 (95% in primary prevention (Petitti, 1998) . Despite a considerable CI 0.65-1.08) for women aged ജ53 years at menopause amount of research, precise epidemiological quantification of compared to those aged Ͻ40. In the National Health and that risk is still lacking. Examination Survey (NHANES) I Study (Cooper and Sandler, 1998) , based on 84 cases of fatal CHD, a moderate, but not significant association was observed between CHD and age at
